India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals
Executive Summary
After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.
You may also be interested in...
Hips Don’t Lie: J&J Faces Compensation Maelstrom In India Over Faulty ASR Implants
Johnson & Johnson is caught in the eye of a storm in India, after an expert panel recommended compensation for patients affected by its 'faulty' ASR hip implants. A stinging report by the panel raises several questions around J&J’s alleged “lack of seriousness” in addressing the issue - charges that the company denies - though it remains to be seen how the Indian government ensures that Indian patients get a fair deal.
Dapagliflozin Alliance Targets Surging Indian Diabetes Market
AstraZeneca has struck an agreement with India’s Sun Pharma under which the two companies will promote and distribute the UK-based firm’s diabetes drug dapagliflozin under different brand names. The deal means AstraZeneca can benefit from Sun’s wide distribution network to penetrate India’s rapidly growing diabetes sector while retaining intellectual property rights.
Forxiga debuts in India at fraction of global prices
The Indian diabetes segment continues to buzz with action. Close on the heels of going through with a second brand plan for saxagliptin, AstraZeneca Pharma has launched Forxiga (dapaglifozin), for type 2 diabetes, on the Indian market at a fraction of international prices.